In addition, SHR-A1307 (47) can effectively kill cancer cells that do not respond to current EGFR inhibitors and shows low nanomolar in vitro cytotoxicity in a broad spectrum of cancer cells with different drug resistance mutations, thus providing an attractive treatment opportunity to overcome the drug resistance of patients with EGFR-overexpressing tumors. The gene discussed is EGFR; the disease is cancer.